Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of ADVM-022 (Ixoberogene soroparvovec) in anti-VEGF–experienced wet age-related macular degeneration
2022-002261-15Phase 2Completed
- Sponsor
- Adverum Biotechnologies
- Start
- Sep 2022
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ixoberogene soroparvovec in exudative macular degeneration, sponsored by Adverum Biotechnologies. Primary endpoint: Incidence and severity of ocular and non-ocular adverse events. Started Sep 2022; status: completed.
02
Drugs
ixoberogene soroparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2022-002261-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002261-15.